23:31 , Jul 14, 2017 |  BioCentury  |  Strategy

Transforming BeiGene

BeiGene Ltd.’s deal with Celgene Corp. for BGB-A317 does more than provide the Chinese biotech with a partner that can compete in the PD-1 space from a development and commercial perspective. It also marks a...
20:29 , May 12, 2017 |  BC Extra  |  Preclinical News

Study explains how macrophages block anti-PD-1 mAbs

In a Science Translational Medicine paper, researchers from Massachusetts General Hospital and Harvard Medical School presented data that may help explain why anti-PD-1 mAbs aren't very effective for some cancer patients, and proposed a way...
07:00 , Jul 29, 2016 |  BC Extra  |  Clinical News

Genentech, AC Immune seek safer mAbs for CNS diseases

In a study published Thursday in Cell Reports, researchers at the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) and AC Immune S.A. (Lausanne, Switzerland) developed a strategy that could make therapeutic antibodies safer for...
08:00 , Dec 15, 2014 |  BioCentury  |  Strategy

Momenta moving on

Data announced in October represent the first fruits of Momenta Pharmaceuticals Inc.'s novel drug pipeline, which will play a larger role in the company's strategy going forward as it steps back from complex generics. Momenta...
07:00 , Jul 9, 2012 |  BioCentury  |  Regulation

Going global in biosimilars

The European Medicines Agency and European Commission have taken steps that will make it easier for biosimilars developers to run global development programs. The changes should save time and money in cases where manufacturing and...
08:00 , Dec 20, 2010 |  BioCentury  |  Regulation

Describing the Inevitable

About a decade ago, conventional wisdom held that mAbs are so complex that it would be extremely difficult, if not impossible, to develop biosimilar versions of them. While some mAb innovators may cling to this...
07:00 , Sep 6, 2010 |  BioCentury  |  Product Development

Promedior avoids redundancy

Promedior Inc. is hoping that blocking monocyte activation will be a better approach for preventing fibrosis than targeting stimulatory cytokines or growth factors, because the cells targeted by its PRM-151 are far enough upstream that...
07:00 , Jul 19, 2010 |  BioCentury  |  Product Development

Selectively seeking SYK

CGI Pharmaceuticals Inc. has created a preclinical library of SYK inhibitors for rheumatoid arthritis and other inflammatory diseases that it believes are best in class because they are more selective than competing compounds in the...
07:00 , May 25, 2009 |  BC Week In Review  |  Company News

Clinical Data, Dana-Farber Cancer Institute deal

Clinical Data's PGxHealth division and the institute will validate genetic variants in Fc gamma receptors (FCGRs) to predict treatment response to Herceptin trastuzumab in patients with breast cancer. The parties will negotiate rights for...
08:00 , Mar 2, 2009 |  BioCentury  |  Strategy

More freedom to deal

With nondilutive cash at a premium, Xencor Inc. is ramping up a partnering campaign built on data that allows the company to expand its XmAb technology into a broader swath of disease areas. The company...